Calprotectin Serum Levels Strongly Predict Disease Flare in RA and Psa Patients with Low Disease Activity Treated with TNF Inhibitors. a One-Year Prospective Cohort Study

被引：0
|
作者：
Inciarte-Mundo, Jose [1 ]
Victoria Hernandez, M. [1 ]
Ruiz-Esquide, Virginia [1 ]
Cabrera-Villalba, Sonia [1 ]
Ramirez, Julio [1 ]
Cuervo, Andrea [1 ]
Pascal, Mariona [2 ]
Yague, Jordi [2 ]
Canete, Juan D. [1 ]
Sanmarti, Raimon [1 ]
机构：
[1] Hosp Clin Barcelona, Dept Rheumatol, Barcelona, Spain
[2] Hosp Clin Barcelona, Dept Immunol, Barcelona, Spain
来源：
ARTHRITIS & RHEUMATOLOGY | 2016年 / 68卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
651
引用
收藏
页数：2
相关论文
共 48 条
  • [1] PREDICTION OF FLARE IN RHEUMATOID ARTHRITIS AND PSORIATIC ARTHRITIS PATIENTS WITH LOW DISEASE ACTIVITY RECEIVING TNF INHIBITORS: ROLE OF CALPROTECTIN AND DRUG TROUGH SERUM LEVELS. A ONE-YEAR PROSPECTIVE COHORT STUDY
    Inciarte-Mundo, J.
    Hernandez, M.
    Ruiz-Esquide, V.
    Ramirez, J.
    Cuervo, A.
    Cabrera-Villalba, S.
    Pascal, M.
    Yague, J.
    Canete, J.
    Sanmarti, R.
    ANNALS OF THE RHEUMATIC DISEASES, 2016, 75 : 968 - 969
  • [2] New biomarkers in monitoring disease activity in AS and PsA patients treated with TNF-α inhibitors.
    Pedersen, Susanne J.
    Hetland, Merete L. ]
    Ostergaard, Mikkel
    Jensen, Trine
    Knudsen, Lene S.
    Krogh, Niels S.
    Nielsen, Hans Jorgen
    Linde, Louise
    Johansen, Julia S.
    ARTHRITIS AND RHEUMATISM, 2006, 54 (09): : S471 - S471
  • [3] SERUM CALPROTECTIN IS NOT PREDICTIVE FOR SUCCESSFUL DOSE REDUCTION OR DISCONTINUATION OF TNF INHIBITORS IN RA PATIENTS WITH LOW DISEASE ACTIVITY
    Den Broeder, N.
    Tweehuysen, L.
    Vogl, T.
    van Herwaarden, N.
    van den Hoogen, F. H. J.
    Thurlings, R. M.
    den Broeder, A. A.
    ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 : 526 - 526
  • [4] Serum Calprotectin Is Not Predictive for Successful Dose Reduction or Discontinuation of TNF Inhibitors in RA Patients with Low Disease Activity
    den Broeder, Nathan
    Tweehuysen, Lieke
    van Herwaarden, Noortje
    Vogl, Thomas
    van den Hoogen, F. H. J.
    Thurlings, Rogier
    Den Broeder, Alfons A.
    ARTHRITIS & RHEUMATOLOGY, 2017, 69
  • [5] IMMUNOGENICITY OF TNF INHIBITORS IN PATIENTS WITH RHEUMATOID ARTHRITIS OR POLYARTICULAR PSORIATIC ARTHRITIS IN CLINICAL REMISSION OR LOW DISEASE ACTIVITY: A ONE-YEAR MULTICENTRE PROSPECTIVE STUDY (THE INMUNOREMAR STUDY)
    Sanmarti, R.
    Inciarte-Mundo, J.
    Estrada-Alarcon, P.
    Garcia-Manrique, M.
    Narvaez, J.
    Gomez-Centeno, A.
    Rodriguez-Moreno, J.
    Pascal, M.
    Yaguee, J.
    ANNALS OF THE RHEUMATIC DISEASES, 2016, 75 : 461 - 461
  • [6] Drug Trough Serum Levels Rather Than Antidrug Antibodies Explain Disease Flares in Patients with Rheumatoid Arthritis and Psoriatic Arthritis Treated with TNF Inhibitors in Clinical Remission/Low Disease Activity: A One Year Prospective, Multicenter Study (INMUNOREMAR)
    Sanmarti, Raimon
    Inciarte-Mundo, Jose
    Estrada, Paula
    Garcia Manrique, Maria
    Narvaez, Javier
    Gomez-Centeno, Antonio
    Rodriguez-Moreno, Jesus
    Pascals, Mariona
    Yague, Jordi
    ARTHRITIS & RHEUMATOLOGY, 2016, 68
  • [7] Remission/Low Disease Activity Is a Reasonable Treatment Target in Psa: Results from a Routine Care European Cohort of Psa Patients Treated with Ustekinumab or TNF Inhibitors
    Gossec, Laure
    Bergmans, Paul
    de Vlam, Kurt
    Gremese, Elisa
    Joven, Beatriz E.
    Korotaeva, Tatiana
    Nurmohamed, Michael
    Sfikakis, Petros
    Siebert, Stefan
    Smirnov, Pavel
    Theander, Elke
    Smolen, Josef S.
    ARTHRITIS & RHEUMATOLOGY, 2018, 70
  • [8] REMISSION/LOW DISEASE ACTIVITY IS A REASONABLE TREATMENT TARGET IN PsA: RESULTS FROM A ROUTINE CARE EUROPEAN COHORT OF PsA PATIENTS TREATED WITH USTEKINUMAB OR TNF INHIBITORS
    Gossec, L.
    Bergmans, P.
    de Vlam, K.
    Gremeses, E.
    Joven-Ibanez, B.
    Korotaeva, T. V.
    Nurmohamed, M. T.
    Sfikakis, P. P.
    Siebert, S.
    Smirnov, P.
    Theander, E.
    Smolen, J.
    JCR-JOURNAL OF CLINICAL RHEUMATOLOGY, 2019, 25 : S65 - S65
  • [9] REMISSION/LOW DISEASE ACTIVITY IS AN ACHIEVABLE TREATMENT TARGET IN PSORIATIC ARTHRITIS (PSA): RESULTS FROM A ROUTINE CARE EUROPEAN COHORT OF PSA PATIENTS TREATED WITH USTEKINUMAB OR TNF INHIBITORS
    Siebert, Stefan
    Gossec, Laure
    Bergmans, Paul
    de Vlam, Kurt
    Gremese, Elisa
    Joven, Beatriz E.
    Korotaeva, Tatiana
    Wright, Pamela B.
    Kent, Toby
    Noel, Wim
    Nurmohamed, Michael
    Sfikakis, Petros
    Smirnov, Pavel
    Theander, Elke
    Smolen, Josef
    RHEUMATOLOGY, 2019, 58 : 144 - 144
  • [10] Adalimumab drug and antidrug antibody levels do not predict flare risk after stopping adalimumab in RA patients with low disease activity
    Lamers-Karnebeek, Femke B. G.
    Jacobs, Johannes W. G.
    Radstake, Timothy R. D. J.
    van Riel, Piet L. C. M.
    Jansen, Tim L.
    RHEUMATOLOGY, 2019, 58 (03) : 427 - 431
12345